Aakash Desai Discusses Key Findings on ADCs in NSCLC Treatment
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted the following on LinkedIn:
“In Cancers MDPI we discuss a key topic ‘Association of Antibody–Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?’
ADCs bring targeted therapy to the next level by delivering cancer-killing agents directly to tumor cells, minimizing harm to healthy tissue.
But… drug-induced interstitial lung disease (D-ILD) remains a challenge.
Key insights from our paper:
- ADCs show potential in NSCLC treatment
- D-ILD risk isn’t solely linked to target expression levels
- Likely factors? Cytotoxic payloads & linker design
What’s next? Safer ADC designs to reduce D-ILD risks while enhancing impact.”
Authors: Aakash Desai, Vivek Subbiah, Sinchita Roy-Chowdhuri, Ajay Sheshadri, Sameer Deshmukh and Solange Peters
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023